209 related articles for article (PubMed ID: 30100080)
1. Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.
Henry KE; Ulaner GA; Lewis JS
PET Clin; 2018 Jul; 13(3):423-435. PubMed ID: 30100080
[TBL] [Abstract][Full Text] [Related]
2. Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 PET Imaging: Challenges and Opportunities.
Ducharme M; Mansur A; Sligh L; Ulaner GA; Lapi SE; Sorace AG
PET Clin; 2023 Oct; 18(4):543-555. PubMed ID: 37339919
[TBL] [Abstract][Full Text] [Related]
3. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.
Henry KE; Ulaner GA; Lewis JS
PET Clin; 2017 Jul; 12(3):269-288. PubMed ID: 28576166
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging of breast cancer.
Oude Munnink TH; Nagengast WB; Brouwers AH; Schröder CP; Hospers GA; Lub-de Hooge MN; van der Wall E; van Diest PJ; de Vries EG
Breast; 2009 Oct; 18 Suppl 3():S66-73. PubMed ID: 19914546
[TBL] [Abstract][Full Text] [Related]
5. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
Okarvi SM; AlJammaz I
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
[TBL] [Abstract][Full Text] [Related]
6. Imaging of human epidermal growth factor receptors for patient selection and response monitoring - From PET imaging and beyond.
Pereira PMR; Abma L; Henry KE; Lewis JS
Cancer Lett; 2018 Apr; 419():139-151. PubMed ID: 29414302
[TBL] [Abstract][Full Text] [Related]
7. Detection of HER2 expression using
Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
[TBL] [Abstract][Full Text] [Related]
8. Targeted nuclear imaging of breast cancer: status of radiotracer development and clinical applications.
Kong FL; Kim EE; Yang DJ
Cancer Biother Radiopharm; 2012 Mar; 27(2):105-12. PubMed ID: 21877909
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P
Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545
[TBL] [Abstract][Full Text] [Related]
10. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
[TBL] [Abstract][Full Text] [Related]
11. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
[TBL] [Abstract][Full Text] [Related]
12. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
13. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.
Kurozumi S; Yamaguchi Y; Matsumoto H; Inoue K; Kurosumi M; Oyama T; Horiguchi J; Fujii T; Shirabe K
Med Mol Morphol; 2019 Jun; 52(2):90-98. PubMed ID: 30259117
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging using PET and SPECT for identification of breast cancer subtypes.
Liu H; Chen Y; Wu S; Song F; Zhang H; Tian M
Nucl Med Commun; 2016 Nov; 37(11):1116-24. PubMed ID: 27438531
[TBL] [Abstract][Full Text] [Related]
15. Development of Gold Nanorods Conjugated with Radiolabeled Anti-human Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody as Single-Photon Emission Computed Tomography/Photoacoustic Dual-Imaging Probes Targeting HER2-Positive Tumors.
Ding N; Sano K; Shimizu Y; Watanabe H; Namita T; Shiina T; Ono M; Saji H
Biol Pharm Bull; 2020; 43(12):1859-1866. PubMed ID: 33268703
[TBL] [Abstract][Full Text] [Related]
16. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
[TBL] [Abstract][Full Text] [Related]
17. HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.
Wehrenberg-Klee E; Sinevici N; Nesti S; Kalomeris T; Austin E; Larimer B; Mahmood U
Mol Imaging Biol; 2021 Dec; 23(6):930-940. PubMed ID: 34101105
[TBL] [Abstract][Full Text] [Related]
18. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
[TBL] [Abstract][Full Text] [Related]
19. PET imaging of a
Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
[TBL] [Abstract][Full Text] [Related]
20. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.
Sandberg D; Tolmachev V; Velikyan I; Olofsson H; Wennborg A; Feldwisch J; Carlsson J; Lindman H; Sörensen J
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1337-1346. PubMed ID: 28261749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
